TCV Trust & Wealth Management Inc. Sells 8,434 Shares of Zoetis Inc. $ZTS

TCV Trust & Wealth Management Inc. lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 12.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 59,551 shares of the company’s stock after selling 8,434 shares during the quarter. TCV Trust & Wealth Management Inc.’s holdings in Zoetis were worth $7,493,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC grew its position in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the last quarter. Global Wealth Strategies & Associates bought a new position in Zoetis in the 4th quarter valued at $25,000. Lodestone Wealth Management LLC bought a new position in Zoetis in the 4th quarter valued at $30,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis in the 3rd quarter valued at $31,000. Finally, Holos Integrated Wealth LLC bought a new position in Zoetis in the 4th quarter valued at $32,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $117.86 on Friday. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The business’s fifty day simple moving average is $122.22 and its 200-day simple moving average is $127.15. The company has a market capitalization of $49.58 billion, a price-to-earnings ratio of 19.58, a PEG ratio of 1.80 and a beta of 0.98.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the prior year, the company earned $1.40 EPS. The business’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio is presently 35.22%.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Morgan Stanley set a $160.00 price objective on Zoetis in a research report on Thursday, December 18th. Finally, Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $152.91.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Argus Research reiterates a Buy on Zoetis, providing an analyst-backed reason for investors to consider accumulation on weakness. Argus Research Remains a Buy on Zoetis (ZTS)
• Positive Sentiment: Zacks publishes pieces positioning Zoetis as both a strong momentum stock and a top value pick — these narratives can attract style-driven flows (momentum/value investors). Here’s Why Zoetis (ZTS) is a Strong Momentum Stock
• Positive Sentiment: Zoetis’s most recent quarterly report beat EPS and revenue estimates and management set FY26 EPS guidance in the ~7.00 range — a fundamental positive that supports medium-term upside as investors digest growth and margins.
• Neutral Sentiment: Broker consensus remains mixed with a consensus “Hold” rating from some brokerage coverage, which can cap upside until more uniformly constructive revisions arrive. Zoetis Inc. (NYSE:ZTS) Given Consensus Rating of “Hold” by Brokerages
• Neutral Sentiment: Sector/market commentary (including Zacks/Yahoo pieces highlighting screening tools) may influence near-term flows but are not company-specific catalysts. Why Investors Need to Take Advantage of These 2 Medical Stocks Now
• Negative Sentiment: Market headlines today report Zoetis shares declining, reflecting short-term profit-taking or broader market weakness rather than new negative fundamental news; this selling pressure is the primary driver of today’s weaker price action. Zoetis (ZTS) Declines More Than Market: Some Information for Investors Zoetis (ZTS) Declines More Than Market: Some Information for Investors

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.